3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
303
Stomach Neoplasms
34
Neoplasm Metastasis
24
Neoplasms
16
Colorectal Neoplasms
16
Breast Neoplasms, Male
16
HER2-positive Breast Cancer
11
Inflammatory Breast Neoplasms
10
Triple Negative Breast Neoplasms
9
Esophageal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
8
Brain Neoplasms
8
Rectal Neoplasms
7
Adenocarcinoma
7
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Pathologic Complete Response
5
Biliary Tract Neoplasms
5
Urologic Neoplasms
4
Salivary Gland Neoplasms
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Ductal, Breast
4
Recurrence
3
Pancreatic Neoplasms
3
Neoplastic Cells, Circulating
3
Multiple Myeloma
3
Meningeal Neoplasms
3
HER2-positive Gastric Cancer
3
Interventions
Paclitaxel
6
Doxorubicin
6
Gemcitabine
4
Bevacizumab
4
pembrolizumab
3
pazopanib
3
durvalumab
3
Sorafenib
3
Docetaxel
3
trebananib
2
spartalizumab
2
cemiplimab
2
brostallicin
2
Propranolol
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Imatinib Mesylate
2
Ifosfamide
2
Carboplatin
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trastuzumab duocarmazine
1
temsirolimus
1
talimogene laherparepvec
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hemangiosarcoma
×
Trastuzumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled